Incapacitating solar urticaria: successful treatment with omalizumab
Abstract: Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Sociedade Brasileira de Dermatologia
2019
|
| Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300331 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|